BACKGROUND: Recent national guidelines recommend use of narrow-spectrum antibiotic therapy as empiric treatment for children hospitalized with community-acquired pneumonia (CAP). However, clinical outcomes associated with adoption of this recommendation have not been studied. METHODS: This retrospective cohort study included children age 3 months to 18 years, hospitalized with CAP from May 2, 2011 through July 30, 2012. Primary exposure of interest was empiric antibiotic therapy, classified as guideline recommended or not. Primary outcomes were length of stay (LOS), total hospital costs, and inpatient pharmacy costs. Secondary outcomes included broadened antibiotic therapy, emergency department revisits, and readmissions. Multivariable linear regression and Fisher exact test were performed to determine the association of guideline-recommended antibiotic therapy on outcomes. RESULTS: Empiric guideline-recommended therapy was prescribed to 168 (76%) of 220 patients. Median hospital LOS was 1.3 days (interquartile range [IQR]: 0.9-1.9 days), median total cost of index hospitalization was $4097 (IQR: $2657-$6054), and median inpatient pharmacy cost was $91 (IQR: $40-$183). Between patients who did and did not receive guideline-recommended therapy, there were no differences in LOS (adjusted -5.8% change; 95% confidence interval [CI]: -22.1 to 12.8), total costs (adjusted -10.9% change; 95% CI: -27.4 to 9.4), or inpatient pharmacy costs (adjusted 14.8% change; 95% CI: -43.4 to 27.1). Secondary outcomes were rare, with no difference in unadjusted analysis between patients who did and did not receive guideline-recommended therapy. CONCLUSIONS: Use of guideline-recommended antibiotic therapy was not associated with unintended negative consequences; there were no changes in LOS, total costs, or inpatient pharmacy costs.
BACKGROUND: Recent national guidelines recommend use of narrow-spectrum antibiotic therapy as empiric treatment for children hospitalized with community-acquired pneumonia (CAP). However, clinical outcomes associated with adoption of this recommendation have not been studied. METHODS: This retrospective cohort study included children age 3 months to 18 years, hospitalized with CAP from May 2, 2011 through July 30, 2012. Primary exposure of interest was empiric antibiotic therapy, classified as guideline recommended or not. Primary outcomes were length of stay (LOS), total hospital costs, and inpatient pharmacy costs. Secondary outcomes included broadened antibiotic therapy, emergency department revisits, and readmissions. Multivariable linear regression and Fisher exact test were performed to determine the association of guideline-recommended antibiotic therapy on outcomes. RESULTS: Empiric guideline-recommended therapy was prescribed to 168 (76%) of 220 patients. Median hospital LOS was 1.3 days (interquartile range [IQR]: 0.9-1.9 days), median total cost of index hospitalization was $4097 (IQR: $2657-$6054), and median inpatient pharmacy cost was $91 (IQR: $40-$183). Between patients who did and did not receive guideline-recommended therapy, there were no differences in LOS (adjusted -5.8% change; 95% confidence interval [CI]: -22.1 to 12.8), total costs (adjusted -10.9% change; 95% CI: -27.4 to 9.4), or inpatient pharmacy costs (adjusted 14.8% change; 95% CI: -43.4 to 27.1). Secondary outcomes were rare, with no difference in unadjusted analysis between patients who did and did not receive guideline-recommended therapy. CONCLUSIONS: Use of guideline-recommended antibiotic therapy was not associated with unintended negative consequences; there were no changes in LOS, total costs, or inpatient pharmacy costs.
Authors: Monica E Kleinman; Leon Chameides; Stephen M Schexnayder; Ricardo A Samson; Mary Fran Hazinski; Dianne L Atkins; Marc D Berg; Allan R de Caen; Ericka L Fink; Eugene B Freid; Robert W Hickey; Bradley S Marino; Vinay M Nadkarni; Lester T Proctor; Faiqa A Qureshi; Kennith Sartorelli; Alexis Topjian; Elise W van der Jagt; Arno L Zaritsky Journal: Pediatrics Date: 2010-10-18 Impact factor: 7.124
Authors: Rachael K Ross; Adam L Hersh; Matthew P Kronman; Jason G Newland; Talene A Metjian; A Russell Localio; Theoklis E Zaoutis; Jeffrey S Gerber Journal: Clin Infect Dis Date: 2014-01-06 Impact factor: 9.079
Authors: Eric Biondi; Russell McCulloh; Brian Alverson; Andrew Klein; Angela Dixon; Shawn Ralston Journal: Pediatrics Date: 2014-06 Impact factor: 7.124
Authors: Ross E Newman; Erin B Hedican; Joshua C Herigon; David D Williams; Arthur R Williams; Jason G Newland Journal: Pediatrics Date: 2012-02-20 Impact factor: 7.124
Authors: Mary Ann Queen; Angela L Myers; Matthew Hall; Samir S Shah; Derek J Williams; Katherine A Auger; Karen E Jerardi; Angela M Statile; Joel S Tieder Journal: Pediatrics Date: 2013-12-09 Impact factor: 7.124
Authors: Karen M Tucker; Tracy L Brewer; Rachel B Baker; Brenda Demeritt; Michael T Vossmeyer Journal: J Spec Pediatr Nurs Date: 2009-04 Impact factor: 1.260
Authors: Derek J Williams; Samir S Shah; Angela Myers; Matthew Hall; Katherine Auger; Mary Ann Queen; Karen E Jerardi; Lauren McClain; Catherine Wiggleton; Joel S Tieder Journal: JAMA Pediatr Date: 2013-09 Impact factor: 16.193
Authors: Nicole M A Le Saux; Jennifer Bowes; Isabelle Viel-Thériault; Nisha Thampi; Julie Blackburn; Melanie Buba; Mary-Ann Harrison; Nick Barrowman Journal: Paediatr Child Health Date: 2020-06-30 Impact factor: 2.253